@prefix jvr: <http://data.loterre.fr/ark:/67375/JVR> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix mesh: <http://id.nlm.nih.gov/mesh/vocab#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

jvr:-BT300B3G-Q
  skos:prefLabel "cerebrospinal fluid (Qualifier)"@en, "liquide cérébrospinal (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-L6C0XPHT-4
  skos:prefLabel "métabolisme (Qualificatif)"@fr, "metabolism (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-XV06LPML-W
  skos:prefLabel "urine (Qualifier)"@en, "urine (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-Q3979798-W
  skos:prefLabel "analysis (Qualifier)"@en, "analyse (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-H7K65Q8S-Z
  skos:prefLabel "radiation effects (Qualifier)"@en, "effets des radiations (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-TJHVZCRZ-0
  skos:prefLabel "administration et posologie (Qualificatif)"@fr, "administration & dosage (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-G30ZJ446-J
  skos:prefLabel "toxicity (Qualifier)"@en, "toxicité (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-NFTHND7Q-8
  skos:prefLabel "intoxication (Qualificatif)"@fr, "poisoning (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-FWD2BGQ0-9
  skos:prefLabel "usage thérapeutique (Qualificatif)"@fr, "therapeutic use (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-THHNVC7V-3
  skos:prefLabel "synthèse chimique (Qualificatif)"@fr, "chemical synthesis (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-D6BND4D8-6
  skos:prefLabel "Ergolines"@fr, "Ergolines"@en ;
  a mesh:Descriptor, skos:Concept ;
  skos:narrower jvr:-T7WT884M-8 .

jvr:-R0ZCQ8X6-J
  skos:prefLabel "agonistes (Qualificatif)"@fr, "agonists (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-S0CS1X5R-5
  skos:prefLabel "immunology (Qualifier)"@en, "immunologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-M63HSDM7-1
  skos:prefLabel "antagonists & inhibitors (Qualifier)"@en, "antagonistes et inhibiteurs (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-HQRFT0C6-B
  skos:prefLabel "isolement et purification (Qualificatif)"@fr, "isolation & purification (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-NB0XHT3S-N
  skos:prefLabel "adverse effects (Qualifier)"@en, "effets indésirables (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-W6SQV79N-S
  skos:prefLabel "classification (Qualifier)"@en, "classification (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-CB30NGKB-3
  skos:prefLabel "economics (Qualifier)"@en, "économie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-G4R176S9-J
  skos:prefLabel "analogs & derivatives (Qualifier)"@en, "analogues et dérivés (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr: a skos:ConceptScheme .
jvr:-SBNWSM1T-R
  skos:prefLabel "history (Qualifier)"@en, "histoire (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-D0F21513-5
  skos:prefLabel "chemistry (Qualifier)"@en, "composition chimique (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-C9JFSVWC-Q
  skos:prefLabel "Agonistes de la dopamine"@fr, "Dopamine Agonists"@en ;
  a mesh:Descriptor, skos:Concept .

jvr:-R3QWLHRG-V
  skos:prefLabel "standards (Qualifier)"@en, "normes (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-T7WT884M-8
  skos:altLabel "LL60K9J05T"@fr, "LL60K9J05T"@en, "477M7SA9N9"@en, "477M7SA9N9"@fr, "1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea"@en, "81409-90-7 (Cabergoline)"@en, "81409-90-7 (Cabergoline)"@fr, "Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8beta)-"@en, "Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8beta)-"@fr ;
  skos:definition "An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE."@en ;
  mesh:allowableQualifier jvr:-NFTHND7Q-8, jvr:-BT300B3G-Q, jvr:-FWD2BGQ0-9, jvr:-NKM836P1-M, jvr:-Q3979798-W, jvr:-CB30NGKB-3, jvr:-W6SQV79N-S, jvr:-R3QWLHRG-V, jvr:-NB0XHT3S-N, jvr:-D0F21513-5, jvr:-G4R176S9-J, jvr:-TJHVZCRZ-0, jvr:-NHL3D2X0-S, jvr:-HQRFT0C6-B, jvr:-WK5F724J-1, jvr:-SBNWSM1T-R, jvr:-L6C0XPHT-4, jvr:-G30ZJ446-J, jvr:-T9HQD7ST-J, jvr:-XV06LPML-W, jvr:-S0CS1X5R-5, jvr:-M63HSDM7-1, jvr:-THHNVC7V-3, jvr:-R0ZCQ8X6-J, jvr:-H7K65Q8S-Z ;
  skos:hiddenLabel "FCE-21336"@fr, "FCE-21336"@en, "Cabaseril"@en, "FCE21336"@fr, "Galastop"@en, "FCE 21336"@en, "1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate"@en, "Cabergoline Diphosphate"@en, "Dostinex"@en, "Cabaser"@en ;
  skos:prefLabel "Cabergoline"@en, "Cabergoline"@fr ;
  a skos:Concept, mesh:Descriptor ;
  skos:broader jvr:-D6BND4D8-6 ;
  owl:sameAs <http://id.nlm.nih.gov/mesh/D000077465> ;
  dc:created "2018-07-09"^^xsd:date ;
  mesh:pharmacologicalAction jvr:-M4W33FZ9-8, jvr:-C9JFSVWC-Q ;
  dc:modified "2018-07-03"^^xsd:date ;
  dc:established "2019-01-01"^^xsd:date ;
  skos:inScheme jvr: .

jvr:-NHL3D2X0-S
  skos:prefLabel "sang (Qualificatif)"@fr, "blood (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-T9HQD7ST-J
  skos:prefLabel "ressources et distribution (Qualificatif)"@fr, "supply & distribution (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-M4W33FZ9-8
  skos:prefLabel "Antiparkinson Agents"@en, "Antiparkinsoniens"@fr ;
  a mesh:Descriptor, skos:Concept .

jvr:-NKM836P1-M
  skos:prefLabel "pharmacology (Qualifier)"@en, "pharmacologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-WK5F724J-1
  skos:prefLabel "pharmacokinetics (Qualifier)"@en, "pharmacocinétique (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .